| pubmed-article:21744082 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21744082 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21744082 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:21744082 | lifeskim:mentions | umls-concept:C0684249 | lld:lifeskim |
| pubmed-article:21744082 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:21744082 | lifeskim:mentions | umls-concept:C0456599 | lld:lifeskim |
| pubmed-article:21744082 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:21744082 | lifeskim:mentions | umls-concept:C0038953 | lld:lifeskim |
| pubmed-article:21744082 | lifeskim:mentions | umls-concept:C1519814 | lld:lifeskim |
| pubmed-article:21744082 | lifeskim:mentions | umls-concept:C1832016 | lld:lifeskim |
| pubmed-article:21744082 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:21744082 | pubmed:dateCreated | 2011-8-12 | lld:pubmed |
| pubmed-article:21744082 | pubmed:abstractText | To present an updated survival analysis of an open-label, parallel-group, phase IIB trial of BLP25 liposome vaccine (L-BLP25) in patients with stage IIIB or IV non-small-cell lung cancer (NSCLC). | lld:pubmed |
| pubmed-article:21744082 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21744082 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21744082 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21744082 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21744082 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21744082 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21744082 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21744082 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21744082 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:21744082 | pubmed:issn | 1432-1335 | lld:pubmed |
| pubmed-article:21744082 | pubmed:author | pubmed-author:MurrayNevinN | lld:pubmed |
| pubmed-article:21744082 | pubmed:author | pubmed-author:SoulièresDeni... | lld:pubmed |
| pubmed-article:21744082 | pubmed:author | pubmed-author:PriceAllanA | lld:pubmed |
| pubmed-article:21744082 | pubmed:author | pubmed-author:CormierYvonY | lld:pubmed |
| pubmed-article:21744082 | pubmed:author | pubmed-author:FalkMartinM | lld:pubmed |
| pubmed-article:21744082 | pubmed:author | pubmed-author:BeierFrankF | lld:pubmed |
| pubmed-article:21744082 | pubmed:author | pubmed-author:EllisPeter... | lld:pubmed |
| pubmed-article:21744082 | pubmed:author | pubmed-author:SawhneyRavind... | lld:pubmed |
| pubmed-article:21744082 | pubmed:author | pubmed-author:MaksymiukAndr... | lld:pubmed |
| pubmed-article:21744082 | pubmed:author | pubmed-author:GossGlenwoodG | lld:pubmed |
| pubmed-article:21744082 | pubmed:author | pubmed-author:ButtsCharlesC | lld:pubmed |
| pubmed-article:21744082 | pubmed:author | pubmed-author:MarshallErnie... | lld:pubmed |
| pubmed-article:21744082 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21744082 | pubmed:volume | 137 | lld:pubmed |
| pubmed-article:21744082 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21744082 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21744082 | pubmed:pagination | 1337-42 | lld:pubmed |
| pubmed-article:21744082 | pubmed:meshHeading | pubmed-meshheading:21744082... | lld:pubmed |
| pubmed-article:21744082 | pubmed:meshHeading | pubmed-meshheading:21744082... | lld:pubmed |
| pubmed-article:21744082 | pubmed:meshHeading | pubmed-meshheading:21744082... | lld:pubmed |
| pubmed-article:21744082 | pubmed:meshHeading | pubmed-meshheading:21744082... | lld:pubmed |
| pubmed-article:21744082 | pubmed:meshHeading | pubmed-meshheading:21744082... | lld:pubmed |
| pubmed-article:21744082 | pubmed:meshHeading | pubmed-meshheading:21744082... | lld:pubmed |
| pubmed-article:21744082 | pubmed:meshHeading | pubmed-meshheading:21744082... | lld:pubmed |
| pubmed-article:21744082 | pubmed:meshHeading | pubmed-meshheading:21744082... | lld:pubmed |
| pubmed-article:21744082 | pubmed:meshHeading | pubmed-meshheading:21744082... | lld:pubmed |
| pubmed-article:21744082 | pubmed:meshHeading | pubmed-meshheading:21744082... | lld:pubmed |
| pubmed-article:21744082 | pubmed:meshHeading | pubmed-meshheading:21744082... | lld:pubmed |
| pubmed-article:21744082 | pubmed:meshHeading | pubmed-meshheading:21744082... | lld:pubmed |
| pubmed-article:21744082 | pubmed:meshHeading | pubmed-meshheading:21744082... | lld:pubmed |
| pubmed-article:21744082 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21744082 | pubmed:articleTitle | Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. | lld:pubmed |
| pubmed-article:21744082 | pubmed:affiliation | Cross Cancer Institute, 11560 University Avenue, Edmonton, AB, T6G 1Z2, Canada. charles.butts@albertahealthservices.ca | lld:pubmed |
| pubmed-article:21744082 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21744082 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:21744082 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21744082 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:21744082 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
